Clinical trial · Interventional
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC
Single-Arm Trial of EBV-Specific TCR-T Cells With Anti-PD1 Auto-secreted Element in the Treatment of EBV-Positive Head and Neck Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epstein-Barr virus (EBV) infections is known to be a high-risk factor to induce nasopharyngeal cancers. To date, EBV-related head and neck squamous cell carcinoma (HNSCC) is still a major concern in east Asia, especially in China. Concurrent therapies for HNSCC have limited response rate and high chance of relapse. However, EBV-induced cancers provided an ideal target for T cell-based immunotherapy due to the non-self origins. Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented EBV antigen become a viable approach to treat this type of cancer. Though engineered T therapies have been well-recognized in hematological cancers, solid cancer treatment has been a major hurdle due to the immune-suppressive tumor microenvironment. One key mechanism of tumor-elicited suppression is the PDL1-PD1 interaction which induces T cell exhaustion. Therefore, TCR-T cells armed with a PD1 antagonist could further enhance the efficacy of TCR-T in solid cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EBV TCR-T
- description
- EBV-specific TCR-T cell with anti-PD1 auto-secreted element
- interventionNames
- Drug: EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Primary outcomes (1)
- measure
- The Maximum Tolerated Dose
- timeFrame
- 8 weeks
- description
- Verify the MTD of TCR-T cells for EBV antigen for treatment. 18 patients will be enrolled in this project, using a dose-escalation approach. The first group of patients will receive 5x10e6/kg TCR-T cells, the second group will receive 1x10e7/kg TCR-T cells, the third group will receive 5x10e7/kg TCR-T cells, the forth group will receive 1x10e8/kg. After confirmation of safety for 5×10e7 dose group, we then added IL-2 on this dose level for consecutive 6 patients. The remaining 6 pts are for enrollment of 1×10e8/kg dose level.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Expected to live longer than 12 weeks * PS 0-2 * Pathology confirmed as EBV positive HNSCC, either metastatic or recurrent disease * Creatinine \<2.5mg/dl * ALT/AST is lower than three times ULN. * No contraindications of leukocyte collection * Before entering the trial, women must adopt a reliable method of contraception until 30 days after infusion. * Understand this trial and have signed an informed consent Exclusion Criteria: * Patients with symptomatic brain metastasis * With other uncontrolled malignant tumors. * Hepatitis B or Hepatitis C activity period, HIV infected patients * Any other uncontrolled disease that interferes with the trial * Patients with severe heart and cerebrovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis and cerebral hemorrhage * Untreated hypertension or hypertensive patients * A person with a history of mental illness that is difficult to control * Researchers do not consider it appropriate to participate in this trial * Patients who have been using immunosuppressive agents for a long time after organ transplants, except for recent or current inhaled corticosteroids * Subjects who have been pregnant or nursing, or who plan for pregnancy within 2 months of treatment or after the end of treatment * An illness affects a person who signs a written consent or complies with a study procedure, or who is unwilling or unable to comply with the research requirements
References
Publications (0)
Data not yet available